Headlands Technologies LLC cut its stake in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Free Report) by 85.5% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 1,198 shares of the specialty pharmaceutical company's stock after selling 7,091 shares during the period. Headlands Technologies LLC's holdings in ANI Pharmaceuticals were worth $66,000 as of its most recent SEC filing.
Other large investors also recently modified their holdings of the company. US Bancorp DE boosted its position in ANI Pharmaceuticals by 842.9% during the 4th quarter. US Bancorp DE now owns 594 shares of the specialty pharmaceutical company's stock worth $33,000 after buying an additional 531 shares during the period. KBC Group NV lifted its holdings in shares of ANI Pharmaceuticals by 89.2% during the fourth quarter. KBC Group NV now owns 1,273 shares of the specialty pharmaceutical company's stock worth $70,000 after purchasing an additional 600 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in shares of ANI Pharmaceuticals by 24.2% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,971 shares of the specialty pharmaceutical company's stock worth $177,000 after purchasing an additional 579 shares during the period. KLP Kapitalforvaltning AS acquired a new stake in ANI Pharmaceuticals in the fourth quarter valued at $166,000. Finally, HighTower Advisors LLC acquired a new position in ANI Pharmaceuticals during the 3rd quarter worth about $222,000. 76.05% of the stock is currently owned by institutional investors.
ANI Pharmaceuticals Stock Up 4.6 %
Shares of ANIP stock traded up $3.00 on Friday, reaching $68.12. 291,286 shares of the company were exchanged, compared to its average volume of 267,570. ANI Pharmaceuticals, Inc. has a one year low of $52.50 and a one year high of $70.00. The company has a market cap of $1.48 billion, a price-to-earnings ratio of -123.85 and a beta of 0.49. The company has a 50-day moving average of $62.34 and a 200-day moving average of $59.07. The company has a debt-to-equity ratio of 1.52, a current ratio of 2.74 and a quick ratio of 1.97.
Insider Buying and Selling at ANI Pharmaceuticals
In related news, SVP Krista Davis sold 1,000 shares of the firm's stock in a transaction dated Friday, March 7th. The shares were sold at an average price of $60.86, for a total value of $60,860.00. Following the transaction, the senior vice president now owns 66,525 shares of the company's stock, valued at approximately $4,048,711.50. This trade represents a 1.48 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP Meredith Cook sold 400 shares of the stock in a transaction that occurred on Thursday, March 13th. The stock was sold at an average price of $63.33, for a total value of $25,332.00. Following the completion of the sale, the vice president now directly owns 80,545 shares of the company's stock, valued at approximately $5,100,914.85. This trade represents a 0.49 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 3,200 shares of company stock valued at $191,776. Company insiders own 12.70% of the company's stock.
Wall Street Analysts Forecast Growth
ANIP has been the subject of several recent research reports. StockNews.com cut ANI Pharmaceuticals from a "hold" rating to a "sell" rating in a research note on Tuesday. JPMorgan Chase & Co. started coverage on shares of ANI Pharmaceuticals in a research report on Wednesday, March 12th. They issued an "overweight" rating and a $85.00 price target on the stock. HC Wainwright reiterated a "buy" rating and set a $94.00 price objective on shares of ANI Pharmaceuticals in a research report on Monday, March 17th. Jefferies Financial Group started coverage on shares of ANI Pharmaceuticals in a report on Friday, March 14th. They issued a "buy" rating and a $80.00 target price on the stock. Finally, Guggenheim reiterated a "buy" rating and set a $86.00 price target on shares of ANI Pharmaceuticals in a report on Friday. One analyst has rated the stock with a sell rating, one has assigned a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $79.75.
Check Out Our Latest Report on ANIP
ANI Pharmaceuticals Profile
(
Free Report)
ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.
Featured Stories
Before you consider ANI Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ANI Pharmaceuticals wasn't on the list.
While ANI Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
